Measuring and targeting aldosterone and renin in atherosclerosis-A review of clinical data

American Heart Journal

Volumn 162, Issue 4, 2011, Pages 585-596

  Hillaert, Marieke A ^a   Lentjes, Eef G ^a   Beygui, Farzin ^b   Kemperman, Hans ^a   Asselbergs, Folkert W ^a   Nathoe, Hendrik M ^a   Agostoni, Pierfrancesco ^a   Voskuil, Michiel ^a   Ivanes, Fabrice ^c   Jude, Brigitte ^c   Bertrand, Michel E ^c   Pasterkamp, Gerard ^a   Van Der Graaf, Yolanda ^a   Doevendans, Pieter A ^a   Montalescot, Gilles ^b   Van Belle, Eric ^c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSINOGEN; APELIN RECEPTOR; CATECHOLAMINE; CELL ADHESION MOLECULE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NITRIC OXIDE; PRORENIN; REACTIVE OXYGEN METABOLITE; RENIN;

ALDOSTERONE BLOOD LEVEL; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL FEATURE; DRUG TARGETING; ENDOTHELIAL DYSFUNCTION; FIBROBLAST; HEART FAILURE; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HUMAN; HYPERTENSION; LIPID OXIDATION; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SODIUM RETENTION; THROMBOGENESIS; WATER RETENTION;

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; ATHEROSCLEROSIS; HUMANS; RENIN;

EID: 80053641993     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2011.06.015     Document Type: Review

References (115)

1. ACE Inhibitor Myocardial Infarction Collaborative Group Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group Circulation 97 1998 2202 2212
2. M.D. Flather, S. Yusuf, and L. Kober Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group Lancet 355 2000 1575 1581 (Pubitemid 30240501)
3. G.R. Dagenais, J. Pogue, and K. Fox Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials Lancet 368 2006 581 588 (Pubitemid 44209181)
4. M.H. Al-Mallah, I.M. Tleyjeh, and A.A. bdel-Latif Angiotensin-converting enzyme inhibitors in coronary artery disease and preserved left ventricular systolic function: a systematic review and meta-analysis of randomized controlled trials J Am Coll Cardiol 47 2006 1576 1583
5. S. Yusuf, K.K. Teo, and J. Pogue Telmisartan, ramipril, or both in patients at high risk for vascular events N Engl J Med 358 2008 1547 1559 (Pubitemid 351522739)
6. S. Yusuf, K. Teo, and C. Anderson Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial Lancet 372 2008 1174 1183
7. J.S. Williams Williams GH. 50th anniversary of aldosterone J Clin Endocrinol Metab 88 2003 2364 2372
8. D.S. Jacoby, and D.J. Rader Renin-angiotensin system and atherothrombotic disease: from genes to treatment Arch Intern Med 163 2003 1155 1164 (Pubitemid 36613067)
9. L.A. Sechi, M. Novello, and G. Colussi Relationship of plasma renin with a prothrombotic state in hypertension: relevance for organ damage Am J Hypertens 21 2008 1347 1353
10. C. Cheng, D. Tempel, and H.R. van Activation of MMP8 and MMP13 by angiotensin II correlates to severe intra-plaque hemorrhages and collagen breakdown in atherosclerotic lesions with a vulnerable phenotype Atherosclerosis 204 2009 26 33
11. V. da Cunha, B. Martin-McNulty, and J. Vincelette Angiotensin II induces histomorphologic features of unstable plaque in a murine model of accelerated atherosclerosis J Vasc Surg 44 2006 364 371 (Pubitemid 44142930)
12. F. Michel, M.L. Ambroisine, and M. Duriez Aldosterone enhances ischemia-induced neovascularization through angiotensin II-dependent pathway Circulation 109 2004 1933 1937 (Pubitemid 38544481)
13. R. Virmani, F.D. Kolodgie, and A.P. Burke Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage Arterioscler Thromb Vasc Biol 25 2005 2054 2061 (Pubitemid 41416300)
14. E. Blessing, M. Preusch, and R. Kranzhöfer Anti-atherosclerotic properties of telmisartan in advanced atherosclerotic lesions in apolipoprotein E deficient mice Atherosclerosis 199 2008 295 303
15. S. Bro, C.J. Binder, and J.L. Witztum Inhibition of the renin-angiotensin system abolishes the proatherogenic effect of uremia in apolipoprotein E-deficient mice Arterioscler Thromb Vasc Biol 27 2007 1080 1086 (Pubitemid 46641961)
16. R. Candido, K.A. Jandeleit-Dahm, and Z. Cao Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice Circulation 106 2002 246 253 (Pubitemid 34761307)
17. J. Cha, V. Ivanov, and S. Ivanova Evolution of angiotensin II-mediated atherosclerosis in ApoE KO mice Mol Med Report 3 2010 565 570
18. S. Keidar, M. Kaplan, and E. Pavlotzky Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone Circulation 109 2004 2213 2220 (Pubitemid 38625399)
19. L. Mazzolai, M.A. Duchosal, and M. Korber Endogenous angiotensin II induces atherosclerotic plaque vulnerability and elicits a th1 response in ApoE-/- mice Hypertension 44 2004 277 282 (Pubitemid 39167222)
20. T. Sasaki, M. Kuzuya, and K. Nakamura AT1 blockade attenuates atherosclerotic plaque destabilization accompanied by the suppression of cathepsin S activity in apoE-deficient mice Atherosclerosis 210 2010 430 437
21. S. Wassmann, T. Czech, and M. van Eickels Inhibition of diet-induced atherosclerosis and endothelial dysfunction in apolipoprotein E/angiotensin II type 1A receptor double-knockout mice Circulation 110 2004 3062 3067 (Pubitemid 39491999)
22. A. Hernandez, L. Barberi, and R. Ballerio Delapril slows the progression of atherosclerosis and maintains endothelial function in cholesterol-fed rabbits Atherosclerosis 137 1998 71 76 (Pubitemid 28175378)
23. S. Hope, P. Brecher, and A.V. Chobanian Comparison of the effects of AT1 receptor blockade and angiotensin converting enzyme inhibition on atherosclerosis Am J Hypertens 12 1999 28 34 (Pubitemid 29118226)
24. K. Song, N. Shiota, and S. Takai Induction of angiotensin converting enzyme and angiotensin II receptors in the atherosclerotic aorta of high-cholesterol fed Cynomolgus monkeys Atherosclerosis 138 1998 171 182 (Pubitemid 28255166)
25. E.M. Lonn, H.C. Gerstein, and P. Sheridan Effect of ramipril and of rosiglitazone on carotid intima-media thickness in people with impaired glucose tolerance or impaired fasting glucose: STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone) J Am Coll Cardiol 53 2009 2028 2035
26. H. Ono, S. Minatoguchi, and K. Watanabe Candesartan decreases carotid intima-media thickness by enhancing nitric oxide and decreasing oxidative stress in patients with hypertension Hypertens Res 31 2008 271 279 (Pubitemid 351461107)
27. M.C. Sinno, and M. Al-Mallah Impact of medical therapy on atheroma volume measured by different cardiovascular imaging modalities Cardiol Res Pract 2010 2010 134564
28. J.G. Wang, J.A. Staessen, and Y. Li Carotid intima-media thickness and antihypertensive treatment: a meta-analysis of randomized controlled trials Stroke 37 2006 1933 1940 (Pubitemid 44297754)
29. K. Yamamoto, H. Ozaki, and K. Takayasu The effect of losartan and amlodipine on left ventricular diastolic function and atherosclerosis in Japanese patients with mild-to-moderate hypertension (J-ELAN) study Hypertens Res 34 2011 325 330
30. J. Kondo, T. Sone, and H. Tsuboi Effect of quinapril on intimal hyperplasia after coronary stenting as assessed by intravascular ultrasound Am J Cardiol 87 2001 443 445 (Pubitemid 32150004)
31. J. Kramer, R.G. Ruf, and S. Schmidt The CAIRP (CAndesartan for In-stent Restenosis Prevention) Trial-a multicenter study of AT1-receptor blocker therapy in coronary stenting J Invasive Cardiol 20 2008 205 210 (Pubitemid 351643265)
32. P.W. Radke, H.R. Figulla, and H. Drexler A double-blind, randomized, placebo-controlled multicenter clinical trial to evaluate the effects of the angiotensin II receptor blocker candesartan cilexetil on intimal hyperplasia after coronary stent implantation Am Heart J 152 2006 761
33. O. Yoshida, H. Hirayama, and M. Nanasato The angiotensin II receptor blocker candesartan cilexetil reduces neointima proliferation after coronary stent implantation: a prospective randomized study under intravascular ultrasound guidance Am Heart J 149 2005 e1 e6
34. G.A. Rodriguez-Granillo, J. Vos, and N. Bruining Long-term effect of perindopril on coronary atherosclerosis progression (from the PERindopril's Prospective Effect on Coronary aTherosclerosis by Angiography and IntraVascular Ultrasound Evaluation [PERSPECTIVE] Study) Am J Cardiol 100 2007 159 163 (Pubitemid 47049630)
35. G.A. Rodriguez-Granillo, W.S. de, and N. Bruining Effect of perindopril on coronary remodelling: insights from a multicentre, randomized study Eur Heart J 28 2007 2326 2331 (Pubitemid 47537773)
36. A. Hirohata, K. Yamamoto, and T. Miyoshi Impact of olmesartan on progression of coronary atherosclerosis: a serial volumetric intravascular ultrasound analysis from the OLIVUS (Impact of OLmesarten on progression of coronary atherosclerosis: evaluation by IntraVascular UltraSound) Trial J Am Coll Cardiol 55 2010 976 982
37. F. Ribichini, V. Ferrero, and A. Rognoni Angiotensin antagonism in coronary artery disease: results after coronary revascularisation Drugs 65 2005
38. P. Biron, M. Chretien, and E. Koiw Effects of angiotensin infusions on aldosterone and electrolyte excretion in normal subjects and patients with hypertension and adrenocortical disorders Br Med J 1 1962 1569 1575
39. J.H. Laragh, M. Angers, and W.G. Kelly Hypotensive agents and pressor substances: the effect of epinephrine, norepinephrine, angiotensin II, and others on the secretory rate of aldosterone in man JAMA 174 1960 234 240
40. J.O. Davis, C.C.J. Carpenter, and C.R. Ayers Relation of renin and angiotensin II to the control of aldosterone secretion Circ Res 11 1962 171 184
41. J.W. Funder Aldosterone action: fact, failure and the future Clin Exp Pharmacol Physiol Suppl 25 1998 S47 S50
42. J. Crabbe Stimulation of active sodium transport by the isolated toad bladder with aldosterone in vitro J Clin Invest 40 1961 2103 2110
43. I.S. Edelman, R. Bogoroch, and G.A. Porter On the mechanism of action of aldosterone on sodium transport: the role of protein synthesis Proc Natl Acad Sci U S A 50 1963 1169 1177
44. H. Hatakeyama, I. Miyamori, and T. Fujita Vascular aldosterone. Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells J Biol Chem 269 1994 24316 24320
45. E.P. Gomez-Sanchez, N. Ahmad, and D.G. Romero Origin of aldosterone in the rat heart Endocrinology 145 2004 4796 4802 (Pubitemid 39551092)
46. N. Ahmad, D.G. Romero, and E.P. Gomez-Sanchez Do human vascular endothelial cells produce aldosterone? Endocrinology 145 2004 3626 3629 (Pubitemid 39037546)
47. M. Lombes, N. Alfaidy, and E. Eugene Prerequisite for cardiac aldosterone action: mineralocorticoid receptor and 11-hydroxysteroid dehydrogenase in the human heart Circulation 92 1995 175 182
48. E.R. Blasi, R. Rocha, and A.E. Rudolph Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats Kidney Int 63 2003 1791 1800 (Pubitemid 36513325)
49. A. Fiebeler, J. Nussberger, and E. Shagdarsuren Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage Circulation 111 2005 3087 3094 (Pubitemid 40847786)
50. R. Rocha, A.E. Rudolph, and G.E. Frierdich Aldosterone induces a vascular inflammatory phenotype in the rat heart Am J Physiol Heart Circ Physiol 283 2002 H1802 H1810
51. G.P. Rossi, V. Di Bello, and C. Ganzaroli Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism Hypertension 40 2002 23 27 (Pubitemid 34755974)
52. J. Suzuki, M. Iwai, and M. Mogi Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation Arterioscler Thromb Vasc Biol 26 2006 917 921 (Pubitemid 43732172)
53. I.Z. Jaffe, and M.E. Mendelsohn Angiotensin II and aldosterone regulate gene transcription via functional mineralocorticoid receptors in human coronary artery smooth muscle cells Circ Res 96 2005 643 650 (Pubitemid 40478331)
54. G. Fejes-Toth, and A. Naray-Fejes-Toth Early aldosterone-regulated genes in cardiomyocytes: clues to cardiac remodeling? Endocrinology 148 2007 1502 1510 (Pubitemid 46457129)
55. Y. Sun, J. Zhang, and L. Lu Aldosterone-induced inflammation in the rat heart: role of oxidative stress Am J Pathol 161 2002 1773 1781 (Pubitemid 35265535)
56. A. Virdis, M.F. Neves, and F. Amiri Spironolactone improves angiotensin-induced vascular changes and oxidative stress Hypertension 40 2002 504 510
57. C.A. Farquharson, and A.D. Struthers Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy Clin Sci (Lond) 103 2002 425 431 (Pubitemid 35193248)
58. C.A. Farquharson, and A.D. Struthers Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure Circulation 101 2000 594 597 (Pubitemid 30094728)
59. J. Blanco-Rivero, V. Cachofeiro, and V. Lahera Participation of prostacyclin in endothelial dysfunction induced by aldosterone in normotensive and hypertensive rats Hypertension 46 2005 107 112 (Pubitemid 40946499)
60. S. Rajagopalan, D. Duquaine, and S. King Mineralocorticoid receptor antagonism in experimental atherosclerosis Circulation 105 2002 2212 2216 (Pubitemid 34517167)
61. S. Takai, D. Jin, and M. Muramatsu Eplerenone inhibits atherosclerosis in nonhuman primates Hypertension 46 2005 1135 1139 (Pubitemid 41533016)
62. E. Van Belle, C. Bauters, and N. Wernert Neointimal thickening after balloon denudation is enhanced by aldosterone and inhibited by spironolactone, and aldosterone antagonist Cardiovasc Res 29 1995 27 32
63. S.M. Keidar, T.M. Hayek, and M.M. Kaplan Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E-deficient mice [Article] J Cardiovasc Pharmacol 41 2003 955 963
64. S. Takai, D. Jin, and M. Sakaguchi The regressive effect of an angiotensin II receptor blocker on formed fatty streaks in monkeys fed a high-cholesterol diet J Hypertens 23 2005 1879 1886 (Pubitemid 41830428)
65. T. Imanishi, H. Ikejima, and H. Tsujioka Addition of eplerenone to an angiotensin-converting enzyme inhibitor effectively improves nitric oxide bioavailability Hypertension 51 2008 734 741 (Pubitemid 351301528)
66. C.A. Lemarie, S.M.C. Simeone, and A. Nikonova Aldosterone-induced activation of signaling pathways requires activity of angiotensin type 1a receptors Circ Res 105 2009 852 859
67. E. Harada, M. Yoshimura, and H. Yasue Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes Circulation 104 2001 137 139 (Pubitemid 32655827)
68. L.J. Min, M. Mogi, and J.M. Li Aldosterone and angiotensin II synergistically induce mitogenic response in vascular smooth muscle cells Circ Res 97 2005 434 442 (Pubitemid 41298173)
69. T. Sugiyama, T. Yoshimoto, and K. Tsuchiya Aldosterone induces angiotensin converting enzyme gene expression via a JAK2-dependent pathway in rat endothelial cells Endocrinology 146 2005 3900 3906 (Pubitemid 41175760)
70. F. Xiao, J.R. Puddefoot, and S. Barker Mechanism for aldosterone potentiation of angiotensin II-stimulated rat arterial smooth muscle cell proliferation Hypertension 44 2004 340 345 (Pubitemid 39167233)
71. D.A. Calhoun Aldosterone and cardiovascular disease: smoke and fire Circulation 114 2006 2572 2574 (Pubitemid 44967338)
72. K. Swedberg, P. Eneroth, and J. Kjekshus Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group Circulation 82 1990 1730 1736 (Pubitemid 20367976)
73. P. Vantrimpont, J.L. Rouleau, and A. Ciampi Two-year time course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) Study Eur Heart J 19 1998 1552 1563 (Pubitemid 28470478)
74. J.L. Rouleau, M. Packer, and L. Moye Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril J Am Coll Cardiol 24 1994 583 591 (Pubitemid 24295729)
75. R. Latini, S. Masson, and I. Anand The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT Eur Heart J 25 2004 292 299 (Pubitemid 38295437)
76. G. Guder, J. Bauersachs, and S. Frantz Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure Circulation 115 2007 1754 1761 (Pubitemid 46648612)
77. F. Beygui, J.P. Collet, and J.J. Benoliel High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction Circulation 114 2006 2604 2610 (Pubitemid 44967343)
78. F. Beygui, G. Montalescot, and E. Vicaut Aldosterone and long-term outcome after myocardial infarction: a substudy of the French nationwide Observatoire sur la Prise en charge hospitaliere, l'Evolution a un an et les caRacteristiques de patients presentant un infArctus du myocarde avec ou sans onde Q (OPERA) study Am Heart J 157 2009 680 687
79. B.R. Palmer, A.P. Pilbrow, and C.M. Frampton Plasma aldosterone levels during hospitalization are predictive of survival post-myocardial infarction Eur Heart J 29 2008 2489 2496
80. F. Ivanes, S. Susen, and F. Mouquet Aldosterone, mortality and acute ischemic events in patients with coronary artery disease outside the setting of acute MI or heart failure Eur Heart J 2011 [Epub ahead of print].
81. A. Tomaschitz, S. Pilz, and E. Ritz Plasma aldosterone levels are associated with increased cardiovascular mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study Eur Heart J 31 2010 1237 1247
82. A.S. Bomback, and P.J. Klemmer The incidence and implications of aldosterone breakthrough Nat Clin Pract Nephrol 3 2007 486 492 (Pubitemid 47313030)
83. B. Pitt, F. Zannad, and W.J. Remme The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators N Engl J Med 341 1999 709 717 (Pubitemid 29407370)
84. B. Pitt, W. Remme, and F. Zannad Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 348 2003 1309 1321 (Pubitemid 36384098)
85. B. Pitt, H. White, and J. Nicolau Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure J Am Coll Cardiol 46 2005 425 431 (Pubitemid 41040281)
86. F. Zannad, J.J.V. McMurray, and H. Krum Eplerenone in patients with systolic heart failure and mild symptoms N Engl J Med 364 2010 11 21
87. E.M. Antman, D.T. Anbe, and P.W. Armstrong ACC/AHA guidelines for the management of patients with st-elevation myocardial infarction-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction) Circulation 110 2004 588 636 (Pubitemid 39036178)
88. K. Swedberg, J. Cleland, and H. Dargie Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology Eur Heart J 26 2005 1115 1140
89. B. Pitt, G. Bakris, and L.M. Ruilope Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) Circulation 118 2008 1643 1650
90. H.R. Brunner, J.H. Laragh, and L. Baer Essential hypertension: renin and aldosterone, heart attack and stroke N Engl J Med 286 1972 441 449
91. A. Slaby, O. Hofman, and R. Reisenauer Plasma renin activity in men with relation to the presence of ischaemic heart disease Atherosclerosis 27 1977 41 48 (Pubitemid 8091429)
92. M.H. Alderman, S. Madhavan, and W.L. Ooi Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension N Engl J Med 324 1991 1098 1104
93. M.H. Alderman, W.L. Ooi, and H. Cohen Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients Am J Hypertens 10 1997 1 8 (Pubitemid 27038966)
94. T.W. Meade, J.A. Cooper, and W.S. Peart Plasma renin activity and ischemic heart disease N Engl J Med 329 1993 616 619 (Pubitemid 23244813)
95. T.J. Wang, P. Gona, and M.G. Larson Multiple biomarkers for the prediction of first major cardiovascular events and death N Engl J Med 355 2006 2631 2639 (Pubitemid 44969122)
96. N.I. Parikh, P. Gona, and M.G. Larson Plasma renin and risk of cardiovascular disease and mortality: the Framingham Heart Study Eur Heart J 28 2007 2644 2652 (Pubitemid 350071528)
97. H.A. Rockman, C. Juneau, and K. Chatterjee Long-term predictors of sudden and low output death in chronic congestive heart failure secondary to coronary artery disease Am J Cardiol 64 1989 1344 1348 (Pubitemid 20000087)
98. G.S. Francis, J.N. Cohn, and G. Johnson Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group Circulation 87 1993 VI40 VI48
99. C.R. Benedict, B. Shelton, and D.E. Johnstone Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction Circulation 94 1996 690 697 (Pubitemid 26289223)
100. T. Tsutamoto, H. Sakai, and T. Tanaka Comparison of active renin concentration and plasma renin activity as a prognostic predictor in patients with heart failure Circ J 71 2007 915 921 (Pubitemid 46833931)
101. D.J. Campbell, M. Woodward, and J.P. Chalmers Prediction of myocardial infarction by N-terminal-pro-B-type natriuretic peptide, C-reactive protein, and renin in subjects with cerebrovascular disease Circulation 112 2005 110 116 (Pubitemid 40962576)
102. J.B. Muhlestein, H.T. May, and T.L. Bair Relation of elevated plasma renin activity at baseline to cardiac events in patients with angiographically proven coronary artery disease Am J Cardiol 106 2010 764 769
103. S. Verma, M. Gupta, and D.T. Holmes Plasma renin activity predicts cardiovascular mortality in the Heart Outcomes Prevention Evaluation (HOPE) study Eur Heart J 2011
104. L.T. Skeggs Jr., J.R. Kahn, and K. Lentz The preparation, purification, and amino acid sequence of a polypeptide renin substrate J Exp Med 106 1957 439 453
105. H.J. Heerspink, V. Perkovic, and Z.D. de Renal and cardio-protective effects of direct renin inhibition: a systematic literature review J Hypertens 27 2009 2321 2331
106. J.E. Frampton, and M.P. Curran Aliskiren: a review of its use in the management of hypertension Drugs 67 2007 1767 1792 (Pubitemid 47263181)
107. P.S. Sever, A.H. Gradman, and M. Azizi Managing cardiovascular and renal risk: the potential of direct renin inhibition J Renin Angiotensin Aldosterone Syst 10 2009 65 76
108. P. Verdecchia, F. Angeli, and G. Mazzotta The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction Vasc Health Risk Manag 4 2008 971 981
109. H. Lu, D.L. Rateri, and D.L. Feldman Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice J Clin Invest 118 2008 984 993 (Pubitemid 351364606)
110. J. Nussberger, J.F. Aubert, and K. Bouzourene Renin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, atenolol, and amlodipine Hypertension 51 2008 1306 1311 (Pubitemid 351555942)
111. J. Pöss, C. Werner, and D. Lorenz The renin inhibitor aliskiren upregulates pro-angiogenic cells and reduces atherogenesis in mice Basic Res Cardiol 105 2010 725 735
112. T. Imanishi, H. Tsujioka, and H. Ikejima Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes Hypertension 52 2008 563 572
113. clinicaltrials.gov. 3-4-2011. 3-4-2011. Ref Type: Internet Communication.
114. D.J. Campbell, J. Nussberger, and M. Stowasser Activity assays and immunoassays for plasma renin and prorenin: information provided and precautions necessary for accurate measurement Clin Chem 55 2009 867 877
115. M.A. Schalekamp, F.H. Derkx, and J. Deinum Newly developed renin and prorenin assays and the clinical evaluation of renin inhibitors J Hypertens 26 2008 928 937 (Pubitemid 351520980)